Thursday, 23 May 2019

Edison Investment Research Posts Update on BioLargo for First Quarter 2019

Edison Investment Research Group published an update on BioLargo, Inc. today internationally through their distribution channels.

You can read the full report at their website HEREand you can also access their original analyst report on BioLargo HERE.









**********************

BioLargo continues to make progress in its goal to establish its various subsidiaries as independent businesses. Odor-No-More recorded revenue of $301,000 for Q119 (of $364,000 total), down 10.7% from Q418. It cited lumpiness in its sales pattern caused by the timing of orders, weather and manufacturing, and the fact that approximately 20% ($68,000) of orders were in process at the end of the quarter. This business is expanding with new distribution agreements in the waste handling and cannabis industries. BioLargo Water has placed it first Advanced Oxidation System (AOS) treatment train, and Clyra Medical will run a 30-day animal study to support a 510(k) application for its wound treatment product.

New deals: Waste handling and cannabis

Odor-No-More signed its fourth national distribution agreement with a major waste handling company and was included on the partner’s purchasing portal. Inclusion in the purchasing portal will make the product available to all operators in the company’s network. The company also announced additional details regarding its initiative to market its CupriDyne Clean products to the cannabis industry: it has signed a five-year distribution agreement with Cannabusters, Inc. to provide CupriDyne Clean as a white-label product. We expect the cannabis industry to grow to over $35bn in 2024, and for it to be a major odor control market. Cannabis cultivation results in the release of large amounts of volatile organic terpenes into the air, which are potent odorants and a potential environmental or health risk.

Clyra in the final stretch

Following FDA feedback that was received shortly before the company’s Q119 report, management is confident that the last piece of data needed to complete the 510(k) application for its wound care product will be a 30-day animal safety study. The company recently completed a preliminary animal study confirming the study protocol, which showed no adverse effects. Once the data from the 30-day animal study is submitted to the FDA, a response is expected in less than 30 days.

AOS: First pilot up and running


BioLargo announced that the first all-in-one AOS water treatment train was placed at a commercial facility as part of its pilot program, a poultry and livestock farm based in Alberta, Canada (Sunworks Farm). This is the second AOS unit placed (the first was its brewery pilot), but the first in which a complete water treatment solution was placed. We expect this program to provide useful feedback on the system and to help establish its utility in a real-world setting.

Thursday, 16 May 2019

BioLargo Quarterly Report Highlights Commercial Progress

Westminster, CA – May 16, 2019 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable products and a full-service environmental engineering company, today announced the filing of its 10-Q quarterly report. As always, company management encourages its stockholders to review the quarterly report which is linked HERE.

Highlights of the company’s commercial progress:













  • Odor-No-More:
    • Revenues for three months ended March 31, 2019 were $364,000, a $101,000 increase over the same period in 2018 – revenue figures do not include $68,000 worth of orders in process as of March 31 which will record in Q2
    • Fourth national purchasing agreement with a waste handling industry leader went live in late March on its centralized purchasing portal, clearing the opportunity for customer operations staff to begin purchasing CupriDyne® Clean
    • Signed a 5-year white-label distribution agreement to sell its disruptive odor and VOC control product CupriDyne Clean into the cannabis and hemp industries under the brand name “Cannabusters” with Cannabusters, Inc., a sister company to Mabre Air Systems 
    • Received the first order for its new product named “CupriDyne Clean Wash” as a one-step solution to wash out trash bins, storage containers and compactors








  • Clyra Medical Technologies:
    • Received the last material request by FDA for the company’s first 510(k) application - commencing a 30-day animal study to confirm that the Clyra product has no adverse effects on wound healing (preliminary study confirmed no adverse effects) (legal disclaimer - while management remains confident that Clyra will ultimately receive premarket clearance for this product, it can make no assurance or prediction as to the success of these efforts)
    • $3M over the past two years has been invested organizing and preparing its antimicrobial and stem cell therapy products to launch into the $2.5B total addressable market
    • Additional technologies are being considered for licensure as Clyra prepares to go to market
















  • BioLargo Water: 
    • Installed its first fully functional Advanced Oxidation System (AOS) treatment train on-site at a poultry and livestock farm in Alberta in the company’s first pre-commercial demonstration pilot
    • Grants awarded total 66 and counting and exceed $3 million in total financial support for the AOS technology
    • Several peer-reviewed publications about the AOS are in progress and will be submitted to high-impact academic journals











  • BioLargo Engineering, Science & Technologies (BLEST):
    • Recently awarded a $100,000 EPA SBIR Phase I grant to develop new methods of eliminating per- and poly-fluoroalkyl substances (PFAS), a group of water contaminants associated with serious health problems including cancer 
    • Playing a critical role supporting BioLargo’s other operating units, as external service engagements with clients continue to expand

BioLargo President & CEO Dennis P. Calvert commented, “Our investments of time and approximately $23 million total capital are now beginning to bear financial fruit and, yet, our current success is only the tip of the iceberg. With the support of our investors we have managed to fully develop and validate three sustainable platform technologies that are destined to serve as cornerstones upon which to build a significant life sciences technology company. We have assembled a team of highly skilled professionals and partners to help us break through the barriers to entry and commercialize our disruptive technologies through strategies including licensure, joint venture, and direct sales.  Notwithstanding the incredible challenges we have faced, we know that our patented technologies hold a bright future and it is our privilege to shepherd them to commercial success.”

About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic wounds to promote infection control and regenerative tissue therapy.

Contact Information
Dennis Calvert President and CEO BioLargo, Inc. 888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Tuesday, 7 May 2019

BioLargo’s CupriDyne Clean and BioLargo Engineering at Waste Expo 2019



Our team is out in force this week at Waste Expo in Las Vegas! Waste Expo is the largest waste handling conference in the United States – it’s attended by the biggest players in solid waste handling, composting, recycling, and more. Our odor division Odor-No-More is showcasing the company’s disruptive odor and VOC control product CupriDyne Clean, which delivers instant odor elimination without the need for fragrances and at lower cost than competitors. Learn more about CupriDyne Clean online here. CupriDyne Clean already has national purchasing agreements signed with four of the top solid waste handling companies in the U.S.

BioLargo’s engineering division is also exhibiting at this year’s Waste Expo. BioLargo’s engineers have decades of experience solving environmental engineering challenges for customers across a vast range of industries, including in waste handling. Their appearance at Waste Expo in 2019 is part of an effort for the engineering division to offer expanded environmental engineering services within the waste handling market where BioLargo’s odor and VOC control division is already selling its disruptive products.





















Monday, 6 May 2019

The AOS Demonstration Pilot and What it Means for BioLargo’s Future


The On-Site AOS Treatment Train

We recently built and installed a sophisticated water treatment system featuring our Advanced Oxidation System (AOS) at a poultry and livestock farm near Edmonton, AB (Sunworks Farm). This pre-commercial pilot will be the first in-field operating AOS system. It is hard to overstate how proud we are of our team for this milestone in the development cycle of the AOS. It’s equally hard to overemphasize how important this milestone is to the commercialization of this amazing technology. When we talk about our AOS technology with stakeholders and investors, a common refrain we hear is, “Sure, but when’s this thing getting out of the research lab and into the real world?” With the news of this treatment train installation, we can answer, “Now”.


















This AOS treatment train has profound implications on both the technological progress of the AOS technology as well as our ability to monetize the AOS. From a technological standpoint, this is a full treatment train containing everything a client needs to treat their wastewater to discharge standards set by regulators. It’s also capable of handling the flowrates required by livestock facilities like this one and is easily scalable to higher flowrates with additional reactors in the treatment train. And importantly, the treatment train is robust enough to function over long periods of time at this poultry farm in any weather. This is a far cry from the lab prototypes that came before. With this new AOS treatment train we have a portable, modular water treatment solution that delivers the highest performance in disinfection and decontamination, eliminates hard-to-treat micropollutants, and has lower operational costs, capital costs, and energy usage rates than other similar water treatment technologies.

From a monetization standpoint, this treatment train can be described as a “test drive” of our business plan for the AOS – we deliver a full treatment solution to a customer in a robust, ruggedized trailer for a free trial period, after which they have the option of keeping the equipment through either lease, purchase, or pay-per-gallon. This is the reason this prototype AOS treatment train truly represents a pivotal moment in the commercialization of the AOS – it’s out of the lab and into the field, where it will soon be earning real money and helping people save on water costs. Furthermore, this pilot system and its integrated on-site laboratory will provide key data and metrics to provide potential customers and is therefore a linchpin for future sales. This is also just our first pre-commercial pilot. Another is being installed at a small brewery in Southern California and it’s also being pulled by industry stakeholders in areas like stormwater, food & beverage, and petrochemical.

It has been a long journey to bring the AOS to this point. It’s worth mentioning that even multi-billion-dollar technology development companies take many years to invent, develop, and commercialize a new water treatment system, and that’s part of why we’re so proud of getting to where we are now with the AOS. At this milestone, it’s worth reflecting on the journey our water technology team has undertaken to bring this technology to bear.


The Early Days of the AOS

Many of you may remember the beginnings of the AOS. The technology was invented by BioLargo’s Chief Science Officer Ken Code. Ken recognized three things: 1) that current water treatment technologies struggled to contend with certain contaminants and pathogens, leading to public health incidents, 2) existing systems were usually very costly and very energy-intensive, and 3) the industry was using the same handful of technologies to treat water virtually everywhere, with little innovation – UV systems, ozone, hydrogen peroxide systems, and chlorine-based systems. Ken conceived of a new technology that exploits electrochemical principles to deliver novel, highly oxidative iodine chemistry that rapidly kills pathogens and oxidizes contaminants. The AOS was born.
















The very first AOS devices bore little resemblance to today’s AOS. Its job was to demonstrate the principle that advanced carbon materials combined with iodine electrochemistry would result in rapid disinfection and decontamination.

Next, the first real lab-scale AOS prototypes were made. Their purpose was to show that the AOS process works in flowing water (we call this a “flow-through reactor”). These were small, fragile, and slow, but they were shown to exhibit tremendous disinfection and decontamination rates in flowing water while consuming surprisingly little electricity.


























The AOS’ Adolescent Years

The next AOS prototypes that were made were a bit bigger – approximate 3” in diameter. These were made to prove that the AOS technology was scalable with size, and that the performance we saw with the smaller reactors wasn’t an artefact of their small size. These new AOS prototypes were capable of processing up to 1L per minute (0.25 gallons). They didn’t win any beauty contests, but they achieved their goal.


























The next step in AOS development was a big one – our first pre-commercial prototype. The purpose of this was to demonstrate that the AOS could be scaled to a size relevant to water treatment in a real, albeit small, commercial setting. It also needed to be equipped with on-board sensor systems that could measure water quality parameters, flow rate, and pressure. To accomplish this, we partnered with an incredibly talented team of sensor developers at the Northern Alberta Institute of Technology’s (NAIT) Centre for Sensors and System Integration (CSSI) in Edmonton. With NAIT, we built the first Alpha Prototype, complete with state-of-the-art sensors, which we showcased at our technical symposium in August of 2016.


















Soon after this, the BioLargo Water team began to work on a new iteration of the AOS – the “Spiral AOS”. This prototype is designed for interior water treatment applications where space is more of a concern and where a compact water treatment platform is preferable. We showcased the AOS late last year on our blog, and you can learn more about it there! The conventional “Stacked” AOS is still used for applications where space is a less important consideration (for example, at a poultry farm). Thanks in part to the modularity of the Spiral design AOS, the technology is now scalable to nearly any required flowrate by adding increasing the number of AOS reactors in a treatment train.


















All Grown Up

The next step in the development of the AOS was to convert this pre-commercial prototype into a packaged device that could actually be used in a field setting. This meant designing what’s referred to as a “treatment train” – meaning all the equipment required to pump, filter, pre-treat, and post-treat the water so that it meets discharge standards and the client doesn’t have to think about it. This was an arduous step, requiring significant capital resources to create the full treatment train you see here. At this stage we also looked to secure agreements with livestock facilities interested in a pre-commercial pilot project. Our treatment train is now installed on-site at Sunworks Farm, a certified organic chicken farm in Alberta interested in the eco-friendly and innovative nature of our AOS technology.


















All of this work could never have been possible without the generous support of government funding agencies like NRC-IRAP, NSERC, Alberta Innovates, and Southern California’s MWD-ICP program. Grants from these organizations helped pay for salaries, equipment, consumables, lab space, office space, and important research collaborations. All in, BioLargo Water has received more than 60 grants to fund its R&D work on the AOS thus far.

Where does the AOS go from here? Another common refrain we hear from our followers and investors is, “When does this thing start making money?” The question is fair enough. Now, thanks to this pilot (and those soon to come), the answer is easier – “Soon.” Pre-commercial pilots like this one are the last stop on the road before commercial pilots, also known as commercial trials. In this pilot we are refining our technical offering at the commercial scale and refining our business model, wherein we offer customers modular, portable treatment trains that simply solve their water issues. Certainly, the journey is not yet over for the commercialization of the AOS that Ken Code invented years ago, but it’s plain to see that the technology has traveled far to get where it is today, and that the journey is nearly over. We couldn’t be more excited for the future of the AOS.